Company News & Events
August 28, 2019
DUSSELDORF, Germany, August 22, 2019 – LenioBio GmbH today announced that the company has been awarded a grant of €2.37 million to accelerate the scale-up of its proprietary protein expression platform ALiCE®
February 22, 2019
LenioBio Announces a Scientific Advisory Board Composed of Experts within the Field of Biotechnology
DUSSELDORF, Germany, February 14, 2019 – LenioBio GmbH announces the appointment of Dr. Lorenz M. Mayr, Prof. Govind Rao, and Prof. Stefan Schillberg to LenioBio’s Scientific Advisory Board (SAB). LenioBio is a German life sciences start-up dedicated to the advancement of a transformative technology for the discovery, development, and expression of ‘difficult-to-produce’ proteins unconstrained by the limitations of the cell.
August 7, 2018
DUSSELDORF and AACHEN, Germany, August 1, 2018 – Life sciences startup LenioBio GmbH and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME announced today the signing of an exclusive license agreement that allows LenioBio to utilize Fraunhofer’s proprietary vector solution and technology for the cryopreservation of cell lysates. In March 2018, LenioBio obtained an exclusive license from Dow AgroSciences LLC to commercialize its proprietary eukaryotic cell-free protein expression technology. The optimized vector solution and cryopreservation technology from Fraunhofer IME has been specifically developed to meet the wide application areas LenioBio is targeting. With the addition of the Fraunhofer IME license, LenioBio is extending the patent family covering this innovative cell-free system and will soon launch its expression kit under the brand name ALiCE®, targeting novel protein developers.
July 16, 2018
INDIANAPOLIS and DUSSELDORF, Germany, March 15, 2018– Proteins are the building blocks of science and the speed, quality and efficiency of protein production research is being advanced through an agreement between Dow AgroSciences LLC, and life sciences startup LenioBio. Today the companies announce an exclusive license to enable LenioBio to utilize Dow AgroSciences’ proprietary eukaryotic cell-free protein expression technology. LenioBio will market the innovation to bio-pharmaceutical developers under the brand name ALiCE™.